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Background: The Austrian diabetes disease management program (DMP) was introduced in 2007 in order to
improve health care delivery for diabetics via the promotion of treatment according to guidelines. Considering the
current low participation rates in the DMP and the question of further promotion of the program, it is of particular
interest for health insurance providers in Austria to assess whether enrollment in the DMP leads to differences in
the pattern of the provision of in- and outpatient services, as well as to the subsequent costs in order to determine
overall program efficiency.
Methods: Historic cohort study comparing average annual levels of in- and outpatient health services utilization
and its associated costs for patients enrolled and not enrolled in the DMP before (2006) and 2 years after (2009) the
implementation of the program in Austria. Data on the use of services and data on costs were extracted from the
records of the Austrian Social Insurance Institution for Business. 12,199 persons were identified as diabetes patients
treated with anti-diabetic medication or anti-diabetics with insulin throughout the study period. 314 diabetics were
enrolled in the DMP.
Results: Patients enrolled in the diabetes DMP received a more evolved pattern of outpatient care, featuring higher
numbers of services provided by general practitioners and specialists (79 vs. 62), more diagnostic services (22 vs. 15)
as well as more services provided by outpatient care centers (9 vs. 6) in line with increased levels of participation in
medical assessments as recommended by the treatment guideline in 2009. Hospitalization was lower for DMP
patients spending 3.75 days in hospital, as compared to 6.03 days for diabetes patients in regular treatment. Overall,
increases in costs of care and medication throughout the study period were lower for enrolled patients (€ 718 vs. €
1.684), resulting in overall costs of € 5,393 p.c. for DMP patients and € 6,416 p.c. for the control group in 2009.
Conclusions: Seen from a health insurance provider’s perspective, the assessment of the Austrian diabetes DMP
shows promising results indicating improved quality of outpatient care as well as overall cost advantages due to
the lower hospitalization rates. Due to methodological limitations of the retrospective study and to the restricted
data access, further promotion of the DMP must be accompanied by prospective research and preferably controlled
trials in order to provide a solid basis for the decision of whether to include diabetes DMP into the insurer’s basic
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Diabetes is commonly regarded as one of the major
causes for premature deaths worldwide. According to
estimates of the world diabetes foundation, 285 million
people were affected by diabetes worldwide in 2010 with
an expected rise of up to 438 million people by 2030
and an overall increase in prevalence from 6.4% (2010)
to 7.8% (2030). Moreover, substantial regional variances
can be observed with highly industrialized countries
such as the United States (8+) or, to a lesser extent,
European Union Member States (3-6%, Austria 4%) fea-
turing the highest share of diabetics because of particu-
lar lifestyles prevalent in these countries associated with
the acquisition of diabetes mellitus type 2. Consequently,
diabetes poses a substantial burden on health care sys-
tems not only due to the fact of lifelong treatment and
the subsequent more frequent use of health care ser-
vices, but also due to severe long-term sequelae as well
as complications associated with unmanaged diabetes,
such as adult blindness, amputations of extremities, car-
diovascular diseases.
As the treatment of (severe) diabetes usually involves
lifelong therapy with anti-diabetic medication and/or the
injection of insulin as well as regular monitoring of the
patients’ health status and subsequent patient involve-
ment, diabetes disease management programs (DMPs)
have been developed in most health systems of indus-
trialized countries. Building on the standardization of
treatment pathway as well as the implementation of
treatment guidelines, DMPs are intended to lead to
coordinated or even integrated health care delivery and
ultimately better health outcomes for participating indi-
viduals at reasonable additional or even lower costs [1-
3].
However, empirical evidence appears to be quite het-
erogeneous in terms of the outcomes of diabetes DMPs
[4]: Whereas several studies found evidence of improved
disease control in terms of intermediate measures such
as HbA1C measurements or eye examinations [5-10],
several authors raised methodological concerns as to
whether these effects are caused by the mere nature of
the DMP or specific biases, mostly selection biases [10-
13]. For health insurance providers, empirical evidence
for changes in utilization of health services and financial
outcomes is inconclusive. Several research groups
[6,10,14,15] have identified reductions in health service
utilization and overall costs, whereas other authors
reported evidence for increased utilization and costs [11]
or inconsistent evidence for a reduction in service
utilization [12,16] or costs [17].
Based on the patient records of diabetics covered by
one of the mandatory health insurance providers in Aus-
tria, the authors therefore seek to assess whether partici-
pation in the disease management program for type 2diabetics would result in different patterns of outpatient
health care service utilization and hospital admission
rates as well as different numbers of prescribed medica-
tion. Taking into account the costs of outpatient health
services received as well as cost estimates for inpatient
care the authors also aim to assess whether the eco-
nomic rationale of disease management can be met by
the Austrian diabetes DMP.
Methods
Population
The authors were granted permission to analyze the
insurer’s records of diabetes patients covered by the So-
cial Insurance Institution for Business in Austria, which
is part of the Austrian mandatory health insurance sys-
tem and covers self-employed and retired self-employed
persons as well as their spouses and children (unless
insured by another social insurance institution due to
occupation). In the year 2009 there were 705,607 per-
sons insured by the Social Insurance Institution for Busi-
ness, 21,299 of whom could be identified as diabetes
patients treated with either oral medication and/or insu-
lin. Diagnosed diabetes patients only following diabetic
diets could not be identified, as health care providers are
not obliged to report data on diagnosis to Austrian so-
cial insurance institutions [18].
Out of the subtotal of 21,299 patients treated with ei-
ther anti-diabetic medication and/or insulin in 2009,
14,408 were identified as diabetics that had already been
treated in 2006. Due to the fact that enrollment onto the
Austrian diabetes DMP was not possible before the be-
ginning of 2007, only this subgroup of 14,408 patients
was included in the subsequent analysis as figures for
2006 would reflect baseline values in order to assess the
impact of participation. Moreover, in order to identify
type 1 diabetics, who do not represent the target popula-
tion of the Austrian DMP and also differ from type 2
diabetics in terms of disease control, the authors per-
formed a separate analysis according to medication in-
take due to the lack of outpatient diagnosis data in
general as well as non-existent access to hospital dis-
charge data. Having excluded patients receiving insulin
only, 12,199 diabetics treated with either oral anti-
diabetics or oral anti-diabetics with insulin could finally
be identified as the study population, out of whom 314
persons were enrolled in the diabetes DMP by 2009.
Table 1 summarizes the characteristics of enrolled as
well as non-participating type 2 diabetics with regard to
sex and age. Whereas no statistically significant differ-
ence could be identified in terms of gender distribution,
diabetics enrolled in the program were on average
3.9 years younger than their non-participating counter-
parts. Further socio-demographic data such as income,
employment status or education were not provided by









66.5 +/− 9.9 69.4 +/− 11.3 <0.001
Sex - no. (%) 0.170
Male 219 (69.7) 7,848 (66.0)
Female 95 (30.3) 4,037 (34.0)
Sex was compared with Pearson's chi-square test, otherwise the Mann–Whitney
U-test was used.
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data protection issues and the subsequent risk of violat-
ing personal rights. However, due to the specific target
population of the insurance institution mainly represent-
ing self-employed or retired self-employed persons as
well as their spouses and children respectively, overall
statistics show that the collective of those insured is
quite homogenous in terms of their socio-demographic
characteristics. The specific population also accounts for
the high share of male diabetes patients, which is also
reflected by a higher portion of men who are insured in
general (61.4% vs. 38.6%) [19].
Characteristics of the Austrian diabetes DMP
In 2004 the Federation of the Austrian Social Insurance
Institutions mandated the Social Insurance Institution of
Styria to lead and coordinate the development of a dia-
betes DMP. The “Therapie Aktiv” program was pre-
sented in 2006 with the first diabetes patients enrolled in
the program in 2007.
As for other disease management programs the Austrian
diabetes DMP is geared towards type 2 diabetics (even
though a share of approx. 10% of enrolled diabetics was
treated with insulin only and had to be excluded from
the study population) and builds upon patient educa-
tion, promotion of self-management, patient registry
and evidence based treatment pathways incorporating
international research as well as recommendations of
the Austrian Society for Diabetes [20]. Overall the pro-
gram aims at (1) the achievement of optimal blood
sugar management, (2) the avoidance or delay of asso-
ciated long-term sequelae and complications, (3) the
reduction of risk of strokes and heart attacks, (4) the
avoidance of harmful side effects of therapy as well as
(5) the promotion of active and self-responsible patient
cooperation [21].
Participation in the Austrian diabetes DMP is volun-
tary for both patients as well as physicians, who may ei-
ther be general practitioners or internists in private
practice. Whereas there is no financial incentive forpatients to enroll in the program, participating physi-
cians benefit from a lump sum payment of € 100 p.a.
for each enrolled patient. Moreover, physicians receive
extra reimbursement for primary consultation to the
amount of € 55 as well as for the delivery of additional
therapeutic medical services inherent to the DMP.
Participating physicians are obliged to do compulsory
training in the field of diabetes management in advance
as well as continuing education. The program features
compulsory checklists as well as a standardized report-
ing system in order support treatment according to
guidelines and coordination of care of all physicians
involved in the process [20]. More enhanced models of
cooperation amongst different providers of outpatient
and inpatient care (’integrated care’) along with ad-
equate payment mechanisms have not been devised so
far, as provision of outpatient care in Austria is predom-
inantly based on self-employed individual physicians,
who generate the majority of their income on a fee-for-
service basis [22].
Outcome measures
As pointed out above, the full set of diabetes patients’
records for outpatient care for 2009, the selected para-
meters on hospitalization (cases, length of stay) and the
overall cost and utilization data for 2006 were made
available to the authors in order to analyze the effects
of the Austrian diabetes DMP in terms of health ser-
vices utilization and process quality of care as well as
its economic effects (cost-cost analysis). In particular,
the following outcome measures were assessed by the
authors:
– Outpatient service utilization
Outpatient service utilization was derived by
calculating the average number of reimbursed
outpatient services per patient provided by each
health profession in 2009. Reimbursed services
include outpatient services provided by general
practitioners and specialists as well as outpatient
care centers and other health professionals.
Moreover, services provided by physicians not
having a contractual relationship with the Social
Insurance Institution for Business (’private
physicians’) are also included in the insurer’s
records as patients receive reimbursement for
four fifths of the contracted fee by the insurance
institution after having consulted a private
physician.
– Hospitalization
Hospital treatment as well as length of stay was
generated on hospital admission and discharge
data included in the insurer’s patient records. In
order to provide homogenous and comparable
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included only inpatient cases in terms of
overnight stays. Figures for diabetes patients
treated in hospitals’ outpatient clinics could not
be collected because only the outpatient health
services within the regular hospital setting (i.e. 0-
days stay) could be identified in the admission
and discharge data. The majority of regular
ambulatory cases treated in hospitals’ outpatient
clinics are not reported to the insurer, because
services provided in outpatient clinics of hospitals
are funded by the centrally pooled hospital funds
on the basis of lump-sum payments [22,23].
Moreover, hospitalization rates only reflect
inpatient treatment in public hospitals. Treatment
in private hospitals not covered by the Social
Insurance for Business is not included. Because
public hospitals account for more than 90% of all
hospital stays in Austria and as private hospitals
mainly reflect small hospitals (sanatoria) focusing
on selective treatments, hospitalization for acute
care is mainly represented by admissions to
public hospitals.
– Treatment according to guidelines
In order to analyze process quality of diabetes
care the authors assessed the frequency of
specific services delivered to patients as
recommended by the reference guideline [21]: (1)
glycosylated hemoglobin (HbA1C) testing, (2)
retinal testing, (3) performed electrocardiogram,
(4) serum lipid testing, (5) microalbumin
assessment, and (6) examination of the status of
blood vessels.
– Costs of care and medication
The average annual costs of outpatient care
and medication for diabetes patients for 2006
(i.e. before the start of the DMP) and 2009
were derived by adding the costs of all
reimbursed outpatient services (see also
outpatient service utilization) to the costs of
prescribed medication.
Due to the central funding of the Austrian
DRG-system (’Leistungsorientierte
Krankenanstaltenfinanzierung’), which features a
retrospective reimbursement of hospitals
administrated by the hospital funds (and not by
each social insurance institution individually),
primary data on costs of inpatient treatment are
not included in the insurer’s patient records [23].
In order to derive overall costs, the authors
included cost calculations for inpatient care by
multiplying average days for inpatient care with
average costs for hospital care as published by the
Austrian ministry of health [24].Data analysis
The study represents a retrospective cohort study com-
paring average annual levels of in- and outpatient health
services utilization as well as its associated costs for
patients enrolled and not-enrolled in the DMP for
diabetes mellitus type 2. Statistical testing was per-
formed using PASW Statistics 18, after having adjusted
the group of non-participating diabetes patients for
age and sex. The authors used Pearson’s chi-square
test for binary variables (sex, patients hospitalized)
and the Mann–Whitney U-test for ordinal metrics
(treatment according to guidelines). For continuous
variables (frequency of in- and outpatient services
utilization, costs) the Kolmogorov-Smirnov D-Test
was applied in order to test for normal distribution.
As all continuous variables tested did not meet the
criterion of normal distribution, the authors used the
Mann–Whitney U-test in order to identify statistically
significant differences. Statistical tests ware applied
two-sided with the confidence interval set at 95%.
Results
Outpatient service utilization
Table 2 summarizes the average number of outpatient
services received by type 2 diabetics for both study
groups in 2009. Overall, patients enrolled in the DMP
received an average number of approx. 185 reimbursed
services p.a., whereas their counterparts receiving regu-
lar diabetes treatment received approx. 191 reimbursed
services.
Table 2 shows major differences between the types of
use of outpatient health services: Patients participating
in the DMP received a higher number of services pro-
vided by general practitioners and medical specialists in
private practice (79 vs. 62), as well as diagnostic services
(22 vs. 15) and services provided by outpatient care cen-
ters (9 vs. 6). On the other hand, non-medical services
such as wound care bandaging (17 vs. 31) and transport
services (8 vs. 31) were more frequently provided to
patients not enrolled in the DMP.
When only looking at professions with significant
differences in terms of services provided to both
groups (p< 0.05), the composition of the identified
professions again reflects the different pattern of health
services utilization. Even more explicitly it can be
shown that medical professions usually involved in
diabetes treatment (general practitioners, internists and
ophthalmologists) as well as ambulatory health care
centers provide a significantly higher number of ser-
vices to DMP patients and also more laboratory ser-
vices. For non-medical services the utilization of
orthopedic shoemaking and transport services turned
out to differ significantly: Patient participating in the
DMP received orthopedic shoemaking more often
Table 2 Health services utilization











Internal medicine 15,89 9,08 6,81 <0.001
General medicine 48,90 41,66 7,24 <0.001
Ophtalmology 6,01 3,66 2,35 <0.001
Dentistry 3,88 3,32 0,56 0.061
Urology 2,50 2,29 0,21 <0.001
Orthopedics 2,16 2,25 −0,09 <0.001
Diagnostic services




3,16 1,57 1,59 <0.001





6,41 4,14 2,27 <0.001
Outpatient clinic for
physical medicine
2,79 1,67 1,12 0.158
Other health
care practitioners




0,32 0,15 0,17 <0.001
Hearing aid
acoustician
0,07 0,05 0,02 0.109
Wound care
bandaging
17,23 31,24 −14,01 0.903
Transport service 7,61 31,09 −23,48 0.019
Other 17,62 19,55 −1,93 <0.001
All services** 185,21 190,65 −5,44 <0.001
* Professions cumulatively accounting for 90% of total reimbursement for
outpatient services are included only.
** All services include all reimbursed outpatient services.
All variables were compared with the Mann–Whitney U-test.









Patients hospitalized - no. (%) 110 (35.0) 4,233 (35.6) 0,833
Average number of hospital
stays (all patients)
0.63 0.80 0.636
Average days spent in
hospital (all patients)
3.75 6.03 0.381
Average number of hospital
stays (patients hospitalized)
1,79 2,24 0.259
Average days spent in
hospital (patients hospitalized)
10,71 16,94 0.007
Average length of hospital
stays (patients hospitalized)
6,32 7,82 0.019
The share of patients hospitalized was compared with Pearson's chi-square
test, otherwise the Mann–Whitney U-test was used.
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quently to the control group.
Hospitalization
The differences within hospitalization rates of type 2 dia-
betics either enrolled in the DMP or receiving regular
treatment are presented in Table 3. In the overall share
of patients being hospitalized in 2009, 35.0% of enrolled
patients received inpatient treatment whereas 35.6% of
non-participating patients were sent to hospital. Whenconsidering the average number of hospital stays as well
as the lengths of stay, the differences between the study
groups become more distinct: the hospitalization of
DMP patients accounted for 1.79 stays and 10.71 hos-
pital days in 2009 whereas his/her counterpart receiving
regular treatment had 2.24 stays and 16.94 hospital days,
with the latter parameter (days spent in hospital) repre-
senting a significant difference (p< 0.05). Overall, dia-
betics enrolled in the DMP spent 3.75 days in hospital in
2009 as compared to 6.03 days in hospital for the con-
trol group, though this difference does not turn out to
be significant for a 95% confidence interval.Treatment according to guidelines
Table 4 provides an overview of various indicators of
process quality of diabetes care by summarizing the fre-
quency of specific medical assessments performed for
both study groups as recommended by the reference
guideline for diabetes treatment [21]. Overall, the ana-
lyzed data show that patients enrolled in the DMP are
more likely to receive structured diabetes care according
to guidelines. All assessed medical services inherent to
evidence based disease management were provided more
frequently to enrolled patients(p< 0.001). In 2009
HbA1C measurements and serum lipids testing
accounted for the most substantial differences in the
share of patients having received no assessment in 2009
(12.7% vs. 36.6% for HbA1C, 14.3% vs. 38.1% for serum
lipids).Costs of care and medication
Table 5 summarizes the total number and costs of out-
patient services as well as medication received by both












none 40 (12.7) 4,353 (36.6)
1 232 (73.9) 6,867 (57.8)
2 42 (13.4) 653 (5.5)
3 0 (0.0) 15 (0.1)




none 156 (49.7) 7,884 (66.3)




none 155 (49.4) 7,755 (65.2)
1+ 159 (50.6) 4,132 (34.8)
Serum lipids - no. (%) <0.001
none 45 (14.3) 4,535 (38.1)
1+ 269 (85.7) 7,353 (61.9)
Microalbumin - no. (%) <0.001
none 206 (65.6) 11,288 (95.0)
1+ 108 (34.4) 599 (5.0)
Status of blood
vessels - no. (%)
<0.001
none 203 (64.6) 9,445 (79.4)
1+ 111 (35.4) 2,443 (20.6)
All variables were compared with Pearson's chi-square test.
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and 2009. As shown above, when discussing outpatient
health services utilization, DMP patients received signifi-
cantly fewer services in 2009 (185 vs. 191 services).
However, due to the larger amount of medical as well as
diagnostic services associated with a larger conformity
to treatment guidelines, total costs of outpatient care
were higher for patients enrolled in the DMP amounting
to € 1,988 while services received by patients in regular
treatment only totaled € 1,615.
Comparing these figures to average costs and
utilization of outpatient care in 2006 (i.e. the year before
the disease management program started), one can first
observe that the average number of services as well as
its associated costs have substantially risen for both
groups, ranging from an increase of 25% for costs for
patients receiving regular treatment to an increase of
40% of services again provided to non-participatingpatients. In contrast, increases in costs and outpatient
services received by enrolled patients appear to be more
consistent (+ 34% for services vs. + 35% for costs) result-
ing in a change of direction in the difference of services
received from 2006 to 2009: Whereas patients who en-
rolled in the DMP later received significantly more ser-
vices than their non-participating counterparts before
the program started. The number of services provided to
those patients in 2009 was significantly lower than the
number for patients in regular treatment. Taking into ac-
count the increase in the differences of costs for out-
patient care from 2006 to 2009 (€ 172 p.c. Vs. € 373 p.c.)
these findings appear to be in line with a more elaborate
pattern of outpatient care for DMP patients as presented
in Table 2.
Contrary to outpatient care, DMP patients received
slightly more prescribed medication (63.5 Vs. 62.9) at
lower costs (€ 1,170 vs. € 1,207). The 2006 figures for
number and costs of medication received show that
increases in prescriptions (+25%) as well as costs (+32%
for DMP patients vs. +34% for non participating
patients) were quite similar for both study groups while
the higher increases in costs for medication in general
reflected price trends for medication in Austria.
When adding the costs for outpatient services to the
medication received, the total costs of outpatient dia-
betes management amounted to € 3,158 for enrolled
patients and € 2,822 for their non-participating counter-
parts in 2009. The overall difference in costs was € 336
p.c. in 2009 (p< 0.001) which was by and large caused
by the reported differences in costs of outpatient care,
whereas costs for medication were slightly lower for
DMP patients. As for medication, 2006 figures revealed
similar tendencies, though the differences in total costs
were lower (€ 157 p.c.) because of differences in the pat-
terns of outpatient care at baseline as well as in its sub-
sequent developments.
When calculating cost estimates for inpatient care
based on average days spent in hospitals for both study
groups as well as average costs for each day spent in
hospitals as presented in official statistics of hospital
accounting [24], one can see that overall costs for care
and medication were substantially lower for patients en-
rolled in the DMP in 2009, representing approximately
85% of the costs for patients receiving regular treatment
(€ 5,393 vs. € 6,416). Comparing these figures to 2006
overall cost estimates, one can still detect higher overall
costs for in- and outpatient care as well as medication
for the control group (€ 4,674 vs. € 4,732), but the over-
all cost difference was substantially lower in 2006,
reflecting only 1% of total costs.
As presented in Table 5, the statistics on inpatient care
show that the increasing divergence in overall costs be-
tween the two study populations is mainly due to increasing














138,47 135,51 <0.001 185,21 190,65 <0.001
Total costs of
service recieved




50,94 50,62 0,376 63,51 62,94 0,383
Total costs of
medication recieved
€ 886,63 € 901,77 0,195 € 1.169,78 € 1.206,64 0,086
Total costs of outpatient
care and medication
€ 2.350,00 € 2.192,94 <0.001 € 3.157,75 € 2.821,70 <0.001
Inpatient care
Average days spent in
hospital (all patients)
3,90 4,26 0,883 3,75 6,03 0.381
Average costs für
inpatient care*
€ 2.324,40 € 2.538,96 n/a € 2.235,00 € 3.593,88 n/a
Overall costs of
care and medication
€ 4.674,40 € 4.731,90 n/a € 5.392,75 € 6.415,58 n/a
* Average costs for each day spent in hospital amounted to € 503 p.d. in 2006 and € 596 p.d. in 2009 (Embacher, 2010).
All variables were compared with the Mann–Whitney U-test.
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and its associated costs: Whereas for patients, who enrolled
in the DMP later the average number of days spent in hos-
pital actually decreased from 2006 to 2009 (3.90 days vs.
3.75 days), the number of average days in hospital increased
for non-participating patients from an average of 4.26 days
in 2006 to 6.03 days in 2009. Even though overall differ-
ences in hospital days did not show statistical significance
in 2009, the differences for the 2009 figures on average days
spent in hospital as well as average length of stay for the
subgroup of hospitalized patients (see Table 3) suggest that
hospitalization rates for patients enrolled in the DMP not
only differ from those of their non-participating counter-
parts, but also that participation in DMP leads to slightly
lower utilization of inpatient care, whereas the control
group experiences substantial increases.
Overall Table 5 illustrates that participation in the DMP
not only led to a shift of health services utilization within
outpatient care, but apparently also from inpatient to
outpatient care in terms of costs, as the group of DMP
patients accounted for lower costs for inpatient care and
higher costs for outpatient services in 2009 as compared
to corresponding figures for 2006 before the start of the
diabetes DMP.
Discussion
The results presented above show that patients enrolled
in the diabetes DMP receive a more evolved pattern ofoutpatient services both in terms of medical services
provided by specialists and ambulatory health care cen-
ters as well as in terms of specific services as put for-
ward by medical guidelines indicating an improved
process quality of outpatient care.
As far as the overall number of outpatient services
received (Table 2) is concerned, these findings are generally
in line with other research: Villagra & Ahmed [6] present
evidence for less frequent use of outpatient services with
DMP patients accounting for significantly fewer office
visits and Dall et al. [7] also observed that active participa-
tion in a diabetes DMP led to a decrease in the number of
ambulatory visits. Contrary to the findings of Villagra &
Ahmed [6] and Dall et al. [7], who also reported lower
costs for overall outpatient care, the authors identified sig-
nificantly higher costs for overall outpatient care of dia-
betes patients receiving treatment within the DMP
(Table 5), which was also found by Buntin et al. [11] when
analyzing insurers data on health care use and costs for
more than 12,000 diabetics.
Analyzing the mere structure of the different out-
patient services as presented in Table 2, it becomes clear
that increased costs for outpatient care for the DMP
group are mainly due to the higher share of enrolled
patients receiving specific diagnostic services according
to the treatment guidelines as opposed to the group of
non-participating patients and is therefore in line with
the intention of disease management. Higher frequencies
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quencies of medical specialist and diagnostic services
performed, which could also be observed by Sidorov
et al. [14], who reported a higher number of outpatient
office visits as well as higher figures of HbA1C testing
and of lipid, eye and kidney screening for DMP patients.
Similarly, other studies reported evidence for a signifi-
cant increase in the frequency of specific examinations
such as HbA1C testing, eye exams, foot exams and chol-
esterol testing due to participation in the DMP [5,10].
The average number of inpatient stays as well as aver-
age length of stay (Table 3)reveals that patients enrolled
in the DMP experienced fewer admissions (0.63 Vs.
0.80) and inpatient days (3.785 Vs. 6.03) per patient,
reflecting a reduction in the latter of more than 40%.
Again, these findings appear to be in line with the results
presented by Sidorov et al. [14], Dall et al. [7] and Villa-
gra & Ahmed et al. [6], who present evidence for a sig-
nificant decline in inpatient days for DMP patients
ranging from 20% to 40%. Considering the fact that the
average hospitalization rates for regular diabetes patients
observed in these US-based studies range between 1 and
1.5 days per patient per year [6,7,14,15], it can be shown,
that even within Austria’s hospital-driven health system,
DMPs lead to similar relative reductions of
hospitalization rates and hence appear to be able to
counterbalance the adverse governance effects primarily
put forward by the characteristics of the Austrian DRG-
system [23].
As observed by Villagra & Ahmed [6] and Dall et al.
[7], it is the overall reduction in inpatient days that
represents the most important source of savings, which
is also reflected by our results on overall cost effects of
DMP enrollment as presented in Table 5. While partici-
pation in the DMP leads to substantial cost advantages
for inpatient care due to steady figures on average days
spent in hospital as opposed to substantial increases in
hospital days for non-participating diabetics from 2006
to 2009, enrollment does not tend to have an overall im-
pact on the amount and costs of prescribed medication.
Villagra and Ahmed [6] and Sidorov et al. [14] observed
similar effects suggesting that disease management is
likely to increase the amount of medication due to
higher adherence to pharmacological regimes on the one
hand, while decreasing the amount of medication due to
appropriate use and better disease control on the other.
Most important, in line with the results presented in
recent studies on the effects of diabetes disease manage-
ment in the UK [25] and in the US [6,7], our findings in-
dicate that even within the Austrian mandatory health
insurance system, which has little competition and free
patient choice in terms of outpatient care, type 2 dia-
betics currently enrolled in the DMP benefit from lower
hospitalization rates as compared to non-participatingpatients. They also benefit from a different pattern of
outpatient care promoting primary and specialist care
associated with higher levels of medical assessments and
tests according to guideline recommendations.
Yet one should acknowledge that participation in the
DMP is still very low amongst type 2 diabetics covered
by the Social Insurance Institution for Business and only
reflects 2.5% of the target population in 2009. These low
participation rates may be due to the specific character-
istics of the insurer’s population, which mainly includes
self-employed persons. Alternatively these figures may
also reflect low overall participation rates throughout
Austria, with the Social Insurance Institution of Styria
leading the field with 8% of enrolled diabetics by the end
of 2009 [26].
As put forward in the introduction, this study ultim-
ately aims to evaluate the effects of diabetes disease
management from an insurer’s perspective. The low
DMP participation rates in Austria mean that health in-
surance providers seem cautious about promoting dis-
ease management. Even though our findings support the
evidence for overall cost advantages for disease manage-
ment, health insurance providers are very unlikely to
benefit from disease management in financial terms, as
more evolved outpatient services remunerated on a fee-
for-service basis lead to higher costs whereas the insur-
ance providers’ financial contributions to the centrally
funded Austrian DRG-system remain constant regardless
of changes in hospitalization rates. Hence, hospital
operators tend to profit from disease management, as
reduced hospitalization rates in terms of hospital stays
cause higher remuneration for the remaining cases and
consequently higher gross margins on the one hand. On
the other, lower average lengths of stay may also contrib-
ute to the financial benefit of hospitals, as for the case of
comparable main diagnosis groups within both study
populations (secondary diagnoses do not have an impact
on Austrian case groups), hospitals receive similar aver-
age lump-sum payments for enrolled and non-
participating patients whereas costs associated with each
particular inpatient stay vary due to the different num-
ber of days spent in hospital [22]. One should therefore
keep in mind that further promotion or even adoption
of diabetes disease management into the basic benefit
package would have to come with the implementation of
adequate remuneration schemes in order to ensure that
insurance providers benefit from cost advantages.
Our study has two basic types of limitations, the first
relating to methodological concerns about the impact of
the assessed outcome measures on overall health out-
come. Several studies report evidence that diabetes
DMPs are associated with better health related quality of
life [27], reduced mortality [28] and in particular inter-
mediate outcomes associated with better control of
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sure and cholesterol levels [5,8-10,29,30].
In our study we only had access to the insurance pro-
vider’s patient records including frequencies as well as
the costs of the reimbursed health services. Information
on intermediate outcomes such asHbA1C level, blood
pressure, cholesterol level is not reported to health
insurers (whether or not patients participated in the
DMP) and can only be collected by either analyzing phy-
sicians’ own patient documentation [13] or direct
inquiry of diabetes patients via questionnaires or inter-
view [5,8]. However, as McEwen et al. [9], Stark et al.
[5], Snyder et al. [19] and Rothe et al. [30] observed
improved healthcare processes in terms of frequency of
specific assessments performed as well as improved
intermediate outcomes, it can well be assumed that the
better treatment conforms to the guideline, the better
overall control of diabetes.
The second type of limitations reflects methodological
concerns, which are due to the design of the study as an
observational retrospective cohort-study. As put forward
by several authors [11-13] selection effects are likely to
occur in population based DMPs. The direction of these
effects is not consistent however: whereas Linder et al.
[12] and Schäfer et al. [13] report that patients with a
better prognosis and lower risk status as well as higher
self-activity and motivation are more likely to be
included in the DMP, Buntin et al. [11] found evidence
for higher utilization of health services and drugs before
enrolment into the DMP which may be associated with
a worse health status of DMP participants as well as
higher motivation or a more stable life situation.
Due to the restricted access to other relevant socio-
demographic characteristics such as income, education,
profession or marital status and the lack of documented
diagnosis in the patient records, the authors could nei-
ther control for socio-demographic differences other
than age and sex between the group of participating and
non-participating patients, nor identify a specific match-
ing control group or matched pairs as suggested by Lin-
der et al. [12] and Miksch et al. [28] respectively.
Schäfer et al. [8] used patient documentation of pri-
mary care physicians of randomly selected diabetes
patients in order to determine differences not only in
social-demographic characteristics, but also in cardiovas-
cular risk profile and patient motivation. Again, these
items are not covered by patient records held by Austrian
mandatory health insurance providers and physicians are
only obliged to perform extended documentation for
patients enrolled in the diabetes DMP [18,31].
Assessing the selection effect of our study, the specific
target population of the insurance institution has to be
taken into account: As pointed out in the presentation
of the population studied, the Social InsuranceInstitution for Business only serves self-employed and
retired self-employed persons as well as their close rela-
tives (spouses, children) unless not covered by another
insurance institution. As socio-economic factors such as
household assets and education (along with race/ethni-
city) have recently proven to be independent predictors
of health decline amongst diabetics over 65 [32] and due
to the fact that variances within socio-economic charac-
teristics within the group of self-employed can be
deemed to be substantially smaller than for regional sub-
sets of the whole population (apart from the fact that
particular lifestyles associated with socio-economic fac-
tors favor the acquisition of diabetes in first place) selec-
tion effects due to economic factors are unlikely to
account for the majority of the observed differences be-
tween the two study groups.
In terms of data on cost and utilization of the study
population before the start of the DMP on the other
hand, we did find substantial differences within the
costs of the services that outpatient received, indicating
a higher share of more expensive services provided to
patients who later enrolled themselves in the DMP.
However, as pointed out above when discussing the dir-
ection of possible selection effects, it remains unclear
whether these differences at baseline are due to the
higher patient involvement for the DMP group or a
worse status of health within this group resulting in
more expensive services. Considering this potential se-
lection effect due to differences in individual as well as
disease-related characteristics of diabetes patients, the
comparison of the 2006 statistics with their corre-
sponding figures for 2009 provides evidence of the effi-
ciency of the Austrian diabetes DMP: Patients who
decided to participate in the program experienced a re-
duction in overall days spent in hospital as well as
lower increases in the number of outpatient services.
This resulted in overall lower costs for care and medi-
cation as compared to their counterparts receiving
regular diabetes treatment.
Conclusions
The overall aim of the study was to assess whether partici-
pation in the Austrian diabetes DMP ultimately leads to
differences in the use of health services and its subsequent
costs as well as treatment according to guidelines in order
to control for patient safety and process quality of care.
This question is of particular relevance for health insurance
providers in order to determine whether further promotion
of DMPs with voluntary participation should be pursued.
As insurance providers adopt a population based perspec-
tive, the analysis of the pattern of health care utilization
must be performed by comparing the actual group of en-
rolled patients to the actual group of non-participating dia-
betics in order to estimate real cost effects.
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fective in promoting a more evolved pattern of outpatient
services delivered and apparently less hospitalization
rates, even though the program’s current rather loose re-
gime of voluntary participation and modest financial
incentives for physicians. Notwithstanding methodo-
logical concerns about selection biases, one should re-
member that analysis and evaluation of particular health
policies such as disease management is always context
specific and hence needs thorough analysis of human be-
havior in order to gain insights into the mechanisms
which can then promote policy learning [33]. In fact, the
authors analyzed the Austrian diabetes DMP with em-
phasis on its internal validity as a whole. Whether the
shift in outpatient care towards services in line with
treatment guidelines was caused by physician promotion
or changed patient demand as a consequence of educa-
tion or both could not be differentiated. Moreover, more
elaborated approaches to diabetes management such as
the chronic care model in integrated care settings which
may even lead to better results [30,34] were beyond the
scope of the study, too, as the authors could only analyze
the effects of the established program within the historic
cohort group
As in other health systems, health insurance providers
and public health politicians face the challenge of
whether or not to adopt disease management as a stand-
ard benefit [4] and of deciding how particular programs
can be set up in order to gain maximum benefit. Our re-
search led to promising results in favor of diabetes dis-
ease management. However, due to the small number of
patients enrolled in the program, future inclusion of
more patients into disease management – either via
increased promotion or via integration into the standard
benefit package – should be accompanied by constant
monitoring. In line with other research [4,11-15,29] we
suggest setting up randomized controlled trials on re-
gional scales in order to enhance empirical evidence on
the effects of the Austrian diabetes DMP with particular
regard to its intermediate outcomes.
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